October 2019 Report

October 2019 Report

NEW DRUG AND FIRST TIME GENERIC

New Drug Pipeline

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Lasmiditan (Reyvow™) Migraine Agent Migraine Headache Treatment Launch pending. Approved October 11, 2019.
Sumatriptan Nasal Spray
(Tosymra™)
Migraine Agent Migraine Headache Treatment Launched October 2019. Approved January 25, 2019.
Buprenorphine/Naloxone
(Cassipa®)
Opioid Agonist/Antagonist Opioid Misuse Disorder Launch pending. Approved September 7, 2018.
Benzhydrocodone HCl/
Acetaminophen
(Apadaz™)
Opioid Analgesic –
Immediate Release
Pain Anticipated second half of 2019. Approved February 23, 2018.
Buprenorphine Depot
Injection
(Brixadi™)
Opioid Agonist Treatment of
Opioid Addiction
Tentatively approved December 26, 2018.
Anticipated in November 2020 following
expiration of exclusivity period for Sublocade™.
Oxycodegol
(Loxicodegol)
Opioid Analgesic – Extended Release Pain FDA review pending.
Oxycodone HCl
(Rexista™)
Opioid Analgesic –
Extended Release
Pain FDA review pending after declining to approve in September 2017.
Naloxone Injection (Zimhi™) Opioid Antagonist Opioid Overdose FDA review pending.
Ubrogepant CGRP Antagonist Migraine Headache Treatment FDA expected to review 4th quarter 2019.
Oxycodone HCl/
Naltrexone HCl
(SequestOx™)
Opioid Analgesic –
Immediate Release
Pain FDA review pending after declining to approve in 2016.

Generic Pipeline

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Hydrocodone Bitartrate
(Zohydro® ER)
Opioid Analgesic – Extended Release Pain Generic anticipated fourth quarter 2019.
Meloxicam
(Vivlodex®)
NSAID Pain Generic anticipated by end of 2019.
Doxepin
(Silenor®)
Tricyclic Antidepressant Sleep Disorders Generic anticipated January 1, 2020.
Naloxone HCl
(Narcan®) Nasal Spray
Opioid Antidote Opioid Overdose Launch pending. Generic approved April 19, 2019.
Emtricitabine/Trenofovir
(Truvada®)
Antiretroviral HIV Post-Exposure Prophylaxis Generic anticipated late 2020

Available in the Last 12 Months

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Solriamfetol
(Sunosi™)
Stimulant Excessive Sleepiness July 2019
Meloxicam
(Qmiiz™ ODT)
NSAID Pain April 2019
Esketamine Nasal Spray
(Spravato®)
Antidepressant Treatment Resistant Depression March 2019
Sufentanil
(Dsuvia™)
Opioid Analgesic –
Immediate Release
Pain February 2019
Cannabidiol
(Epidiolex®)
Cannabinoid Seizures November 2018

 

Newly Available Generics

Medication (Trade Name) Drug Class Therapeutic Use Status Update
Pregabalin
(Lyrica®)
Anticonvulsant Neuropathic Pain July 2019
Cyclobenzaprine HCl
(Amrix®)
Skeletal Muscle Relaxant Muscle Spasm March 2019
Fluticasone/Salmeterol
(Advair Diskus®)
Asthmatic Agent Asthma and COPD February 2019
Buprenorphine/Naloxone
(Suboxone®)
Opioid Agonist/Antagonist Opioid Misuse
Disorder
February 2019